-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target

Benzinga·07/13/2026 13:14:47
Listen to the news
Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.